Courtney Flaherty

The phase 2 trial of the gamma-delta T-cell therapy INB-400 plus temozolomide in patients with newly diagnosed GBM has suspended enrollment.

Phase 2 data show meaningful efficacy with taletrectinib regardless of whether patients with ROS1-positive NSCLC previously received tyrosine kinase inhibitors.

Joshua Linscott, MD, PhD, discusses the use of urinary cell-free tumor DNA for MRD detection prior to repeat resection in high-risk NMIBC.

Neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, improved overall survival in triple-negative breast cancer.

Thomas Pwles, MBBS,

Tislelizumab has been approved by the Israeli Ministry of Health for pretreated patients with unresectable or metastatic esophageal squamous cell carcinoma.

The HERTHENA-Lung02 trial met its primary end point of improved PFS with patritumab deruxtecan in pretreated EGFR-mutated non–small cell lung cancer.

Moshe Ornstein, MD, MA, discusses the implications of updates to NCCN guidelines for the management of non–clear cell and clear cell renal cell carcinoma

Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.

R. Lor Randall, MD, FACS, discusses the relationship between poverty, race, ethnicity, and survival outcomes in pediatric nonmetastatic osteosarcoma.